Generate Biomedicines, Inc. (GENB) · Peers
Generate Biomedicines against the 340 other companies here in its SEC industry, Pharmaceutical Preparations. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 341, highest first.
Measure by measure
| Measure | GENB | Peer median | Rank |
|---|---|---|---|
| Market value | $1.61B | median $244.45M | 91 of 333 |
| P/S | 119.1× | median 6.4× | 35 of 292 |
| FCF yield | -8.9% | median -11.9% | 144 of 319 |
| Operating margin | -1002.6% | median -38.9% | 206 of 228 |
| Net margin | -950.7% | median -30.0% | 213 of 222 |
| ROE | -28.2% | median -37.4% | 124 of 276 |
| Current ratio | 10.6× | median 3.7× | 68 of 325 |
| Stock pay / revenue | 108.1% | median 11.6% | 59 of 281 |
Green where Generate Biomedicines is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.
The peers, largest first
| Company | Market value | P/E | ROIC | Score |
|---|---|---|---|---|
| GENBGenerate Biomedicines, Inc. | $1.61B | P/E – | – | 3.9 |
| LLYELI LILLY & Co | $1.18T | P/E 44.2× | 41.2% | 6.8 |
| JNJJohnson & Johnson | $611.61B | P/E 29.1× | 18.2% | 6.6 |
| ABBVAbbVie Inc. | $499.53B | P/E 79.2× | 25.6% | 5.7 |
| MRKMerck & Co., Inc. | $360.90B | P/E 113.7× | 6.2% | 5.3 |
| NVSNovartis AG ADR | $286.93B | P/E 20.5× | 21.2% | 7.4 |
| AZNAstraZeneca PLC | $256.54B | P/E 25.1× | 14.6% | 7.2 |
| GSKGSK plc | $213.52B | P/E 25.8× | 20.1% | 7.2 |
| ABTAbbott Laboratories | $181.25B | P/E 28.9× | 9.8% | 6.3 |
| NVONovo Nordisk A/S | $171.70B | P/E 11.3× | 31.6% | 7.3 |
| PFEPfizer Inc | $167.74B | P/E 21.6× | – | 5.8 |
| VRTXVertex Pharmaceuticals Inc | $127.22B | P/E 28.9× | 30.2% | 7.3 |
| BMYBristol-Myers Squibb Company | $120.17B | P/E 12.9× | 17.1% | 7.9 |
| REGNRegeneron Pharmaceuticals Inc | $82.90B | P/E 19.2× | 11.5% | 6.8 |
| SNYSanofi | $48.26B | P/E 5.5× | 6.0% | 6.9 |
| TEVATeva Pharma Industries Ltd ADR | $48.14B | P/E 68.2× | 14.8% | 6.4 |
| ONCBeOne Medicines Ltd. | $38.79B | P/E 59.2× | 69.3% | 7.6 |
| RPRXRoyalty Pharma plc | $33.56B | P/E 41.2× | 6.5% | 6.9 |
| ZTSZoetis Inc. | $32.89B | P/E 12.6× | 27.8% | 7.1 |
| ALNYAlnylam Pharmaceuticals Inc | $31.22B | P/E 42.6× | – | 6.6 |
| GMABGenmab AS | $23.67B | P/E 24.6× | 8.8% | 6.5 |
| UTHRUNITED THERAPEUTICS Corp | $23.30B | P/E 17.8× | 29.6% | 7.8 |
| VTRSViatris Inc | $20.97B | P/E 364.1× | -0.3% | 5.5 |
| INSMINSMED Inc | $20.81B | P/E – | -399.1% | 4.8 |
| ASNDAscendis Pharma A/S | $14.25B | P/E – | -20.6% | 4.0 |
| JAZZJazz Pharmaceuticals plc | $13.53B | P/E 14.4× | -4.1% | 6.5 |
| BBIOBridgeBio Pharma, Inc. | $13.28B | P/E – | – | 3.5 |
| SMMTSummit Therapeutics Inc. | $12.42B | P/E – | – | – |
| CORTCorcept Therapeutics Incorporated | $12.12B | P/E 219.6× | 1.3% | 5.0 |
| ELANElanco Animal Health Inc | $11.74B | P/E – | – | 5.4 |
| BMRNBiomarin Pharmaceutical Inc | $10.58B | P/E 145.0× | 1.1% | 4.8 |
| MDGLMadrigal Pharmaceuticals Inc | $10.39B | P/E – | -989.2% | 4.8 |
| CRNXCrinetics Pharmaceuticals, Inc. | $9.01B | P/E – | – | 4.1 |
| CYTKCytokinetics Inc | $8.71B | P/E – | – | 2.3 |
| PTGXProtagonist Therapeutics, Inc | $8.41B | P/E 101.4× | – | 6.8 |
| AXSMAxsome Therapeutics, Inc. | $8.16B | P/E – | – | 4.7 |
| TGTXTG Therapeutics, Inc. | $8.16B | P/E 18.5× | 13.5% | 5.3 |
| ARWRArrowhead Pharmaceuticals, Inc. | $8.08B | P/E – | – | 4.5 |
| SYRESpyre Therapeutics, Inc. | $7.47B | P/E – | – | 3.2 |
| IONSIonis Pharmaceuticals Inc | $7.38B | P/E – | -74.6% | 2.6 |
| ALKSAlkermes plc. | $7.21B | P/E 109.0× | 3.4% | 4.6 |
And 300 smaller ones.
The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.